Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.
Also called NCT01541215
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 135 participants
- Sponsor
- Registry
-
NCT01541215 -
2011-002605-29 -
CTRI/2013/10/004082
-
- Other papers using this trial's data
- Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Brazil, Canada, Croatia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Israel, Italy, Lebanon, Malaysia, Mexico, Morocco, Netherlands, New Zealand, North Macedonia, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01541215. Randomized; double masking; primary purpose treatment. Start 2012-11-13 (actual); primary completion 2017-11-15 (actual). Results posted on 2018-12-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
- Acronym
- Ellipse™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- placebo
- Intervention (Drug)
- metformin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01541215- Content hash
cccbdd7042275b23d8aea72124aedb78d1837917b033301ac2d404ad37762fbd